Thyroid-stimulating hormone suppression therapy for differentiated thyroid cancer: The role for a combined T3/T4 approach.

about

Thyroid-stimulating hormone suppression therapy for differentiated thyroid cancer: The role for a combined T3/T4 approach.

Item

http://www.wikidata.org/entity/Q48270692

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Thyroid-stimulating hormone su ...... for a combined T3/T4 approach.

@en

Thyroid-stimulating hormone su ...... for a combined T3/T4 approach.

@nl

type

Item

label

Thyroid-stimulating hormone su ...... for a combined T3/T4 approach.

@en

Thyroid-stimulating hormone su ...... for a combined T3/T4 approach.

@nl

prefLabel

Thyroid-stimulating hormone su ...... for a combined T3/T4 approach.

@en

Thyroid-stimulating hormone su ...... for a combined T3/T4 approach.

@nl

P1476

Thyroid-stimulating hormone su ...... for a combined T3/T4 approach.

@en

P2093

Farhan Ahsan

http://www.w3.org/2001/XMLSchema#string

Habib Khan

http://www.w3.org/2001/XMLSchema#string

Laura Pettit

http://www.w3.org/2001/XMLSchema#string

Ravi Prashant

http://www.w3.org/2001/XMLSchema#string

P2860

Thyroid Hormone Replacement in Patients Following Thyroidectomy for Thyroid Cancer

Subclinical thyroid dysfunction and incident hip fracture in older adults

Combined thyroxine/liothyronine treatment does not improve well-being, quality of life, or cognitive function compared to thyroxine alone: a randomized controlled trial in patients with primary hypothyroidism.

Does a combination regimen of thyroxine (T4) and 3,5,3'-triiodothyronine improve depressive symptoms better than T4 alone in patients with hypothyroidism? Results of a double-blind, randomized, controlled trial.

Replacement therapy with levothyroxine plus triiodothyronine (bioavailable molar ratio 14 : 1) is not superior to thyroxine alone to improve well-being and cognitive performance in hypothyroidism.

Partial substitution of thyroxine (T4) with tri-iodothyronine in patients on T4 replacement therapy: results of a large community-based randomized controlled trial.

Thyroid hormone replacement therapy in primary hypothyroidism: a randomized trial comparing L-thyroxine plus liothyronine with L-thyroxine alone.

Effects of thyroxine as compared with thyroxine plus triiodothyronine in patients with hypothyroidism.

Thyroxine-triiodothyronine combination therapy versus thyroxine monotherapy for clinical hypothyroidism: meta-analysis of randomized controlled trials.

Common variation in the DIO2 gene predicts baseline psychological well-being and response to combination thyroxine plus triiodothyronine therapy in hypothyroid patients.

P304

2567-2572

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/HED.24926

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Jonathan M Fussey

P577

2017-09-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28960722

http://www.w3.org/2001/XMLSchema#string